First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial

Cytryn, S. L., Moy, R. H., Cowzer, D., Shah, R. H., Chou, J. F., Joshi, S. S., Ku, G. Y., Maron, S. B., Desai, A., Yang, J., Sugarman, R., Rao, D., Goldberg, Z., Charalambous, C., Lapshina, M., Antoine, A., Socolow, F., Trivedi, N., Capanu, M., … Janjigian, Y. Y. (2023). First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. The Lancet Oncology, 24(10), 1073–1082. https://doi.org/10.1016/s1470-2045(23)00358-3
Authors:
Samuel L Cytryn
Ryan H Moy
Darren Cowzer
Ronak H Shah
Joanne F Chou
Smita S Joshi
Geoffrey Y Ku
Steven B Maron
Avni Desai
Jessica Yang
Ryan Sugarman
Devika Rao
Zoe Goldberg
Carmelina Charalambous
Maria Lapshina
Ariel Antoine
Fiona Socolow
Nikhil Trivedi
Marinela Capanu
Hans Gerdes
Mark A Schattner
Marc Simmons
Mario E Lacouture
Viktoriya Paroder
Laura H Tang
Jinru Shia
David H Ilson
David B Solit
Michael F Berger
Yelena Y Janjigian
Affiliated Authors:
Ryan H Moy
Columbia Affiliation:
Subjects:
Adenocarcinoma (MeSH)
Esophageal Neoplasms (MeSH)
Exanthema (MeSH)
Stomach Neoplasms (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1016/s1470-2045(23)00358-3
PMID:
37666264
DOI:
10.1016/s1470-2045(23)00358-3
Journal:
Lancet Oncology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record

Record Created: